Infliximab and adalimumab for the treatment of Crohn's disease

  • Technology appraisal guidance
  • TA187
  • Published: 
Download guidance (PDF)

Update information

February 2014: Implementation section updated to clarify that infliximab and adalimumab are recommended as options for treating Crohn's disease.

ISBN: 978-1-4731-7087-2